Gastrointestinal Cancer

Gastrointestinal Cancer

Looking at a large group of early-onset colorectal cancer patients, only 1.3% had TP53 mutations, none of whom met criteria for Li-Fraumeni syndrome.

Current use of statins was associated with about a 50% decreased risk for liver cancer, according to results of a study looking at data from the United Kingdom.

A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.

If US colorectal cancer screening is increased to 80% by 2018, a new study predicts a decrease in both cancer incidence and mortality within 20 years.

Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.

Although genomic testing can improve the cost-effectiveness of a treatment, assessing the cost-effectiveness of genomic testing outside the context of its impact on treatment is not practical.

The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.


Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.